XML 45 R26.htm IDEA: XBRL DOCUMENT v3.4.0.3
(LOSS) EARNINGS PER SHARE
 12 Months Ended
Dec. 31, 2015
Earnings Per Share [Abstract]  
(LOSS) EARNINGS PER SHARE
(LOSS) EARNINGS PER SHARE
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc. for the years ended December 31, 2015, 2014 and 2013 were calculated as follows:
 
 
2015
 
2014
(Restated)
 
2013
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.
 
$
(291.7
)
 
$
880.7

 
$
(866.1
)
Basic weighted-average number of common shares outstanding
 
342.7

 
335.4

 
321.0

Dilutive effect of stock options and RSUs
 
—

 
6.1

 
—

Diluted weighted-average number of common shares outstanding
 
342.7

 
341.5

 
321.0

 
 
 
 
 
 
 
(Loss) earnings per share attributable to Valeant Pharmaceuticals International, Inc.:
 
 
 
 
 
 
Basic
 
$
(0.85
)
 
$
2.63

 
$
(2.70
)
Diluted
 
$
(0.85
)
 
$
2.58

 
$
(2.70
)

In 2015 and 2013, all stock options, RSUs and convertible notes were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been as follows:
 
2015
 
2013
Basic weighted-average number of common shares outstanding
342.7

 
321.0

Dilutive effect of stock options and RSUs
6.1

 
6.5

Diluted weighted-average number of common shares outstanding
348.8

 
327.5


In 2015, 2014 and 2013, stock options to purchase approximately 134,000, 877,000 and 1,090,000 common shares of the Company, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method.